Abstract
Bioprosthetic heart valves are often preferred over mechanical valves as they may preclude the need for anticoagulation. Reoperation is the standard treatment for structural failure of bioprosthetic valves; however, it carries significant risk especially in inoperable elderly patients. Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) seems to be an effective and promising procedure in patients with degenerated bioprosthetic aortic valves avoiding the risks associated with the use of cardioplegia and redo cardiac surgery. We report an interesting case of a high-risk 74-year-old patient with a degenerated Sorin Freedom Solo stentless valve treated successfully with ViV TAVR.
MeSH terms
-
Aged
-
Aortic Valve Insufficiency* / diagnosis
-
Aortic Valve Insufficiency* / etiology
-
Aortic Valve Insufficiency* / physiopathology
-
Aortic Valve Insufficiency* / surgery
-
Aortic Valve Stenosis* / diagnosis
-
Aortic Valve Stenosis* / physiopathology
-
Aortic Valve Stenosis* / surgery
-
Aortic Valve* / pathology
-
Aortic Valve* / surgery
-
Bioprosthesis / adverse effects*
-
Echocardiography / methods
-
Heart Valve Prosthesis / adverse effects
-
Heart Valve Prosthesis Implantation* / adverse effects
-
Heart Valve Prosthesis Implantation* / instrumentation
-
Heart Valve Prosthesis Implantation* / methods
-
Humans
-
Male
-
Monitoring, Intraoperative / methods
-
Postoperative Complications / diagnosis
-
Postoperative Complications / physiopathology
-
Postoperative Complications / surgery
-
Prosthesis Failure / adverse effects*
-
Reoperation / methods
-
Severity of Illness Index
-
Transcatheter Aortic Valve Replacement / methods*
-
Treatment Outcome